Abediterol
- Generic Name
- Abediterol
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30F2N2O4
- CAS Number
- 915133-65-2
- Unique Ingredient Identifier
- QXA167CM6F
- Background
Abediterol has been used in trials studying the treatment of Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Obstructive Pulmonary Disease (COPD) and Asthma.
Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers.
Phase 1
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT04199598
- Locations
- 🇩🇪
Research Site, Berlin, Germany
To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT03273127
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Asthma
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT02967159
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02777827
- Locations
- 🇩🇪
Research Site, Wiesbaden, Germany
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT01425814
- Locations
- 🇩🇪
Almirall Investigational Sites#6, Frankfurt, Germany
🇩🇪Almirall Investigational Sites#3, Grosshansdorf, Germany
🇩🇪Almirall Investigational Sites#8, Lübeck, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath